ノースカロライナにおける小細胞肺がんの臨床試験
ノースカロライナ内の拠点で、小細胞肺がんに関する16件の研究が参加者を募集しています。
ノースカロライナ内の都市
公式研究テキスト（英語）
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Duke University, Durham
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Cape Fear Valley Cancer Center, Fayetteville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07472517A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
- GSK Investigational Site, Wilson
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07099898DESTINY-PANTUMOUR04
- Research Site, Durham
- Research Site, Wilson
被験者募集中観察研究
18歳〜130歳 · 全性別 · 2026/09/25更新 · NCT07124000A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
- FirstHealth of the Carolinas- Speciality Center /ID# 279857, Pinehurst
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07365241A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Duke Cancer Center Durham, Durham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07488676Study of Trilaciclib and Lurbinectidin
- Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/21更新 · NCT05578326A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
- Duke Cancer Institute, Durham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT07325136A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Duke Cancer Institute, Durham
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06646276A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, Huntersville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/06更新 · NCT07749586A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- University of North Carolina at Chapel Hill, Chapel Hill
- Duke University Medical Center, Durham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/15更新 · NCT05652686Tempus Small Cell Lung Cancer Observational Study (Sculptor)
- University of North Carolina, Chapel Hill
被験者募集中観察研究
18歳以上 · 全性別 · 2026/06/15更新 · NCT05257551Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
- FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst
被験者募集中第2相
18歳以上 · 全性別 · 2026/03/30更新 · NCT06769126Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
- Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC, Salisbury
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/03/11更新 · NCT06681220Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- Carolina BioOncology Institute, Huntersville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/02/18更新 · NCT07030257Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
- Lineberger Comprehensive Cancer Center, Chapel Hill
被験者募集中早期第1相
18歳以上 · 全性別 · 2026/02/05更新 · NCT05620342ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。